title: Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice.
abstract: OBJECTIVE
  Melanin-concentrating hormone (MCH) is a cyclic orexigenic neuropeptide predominantly expressed in the lateral hypothalamus. We investigated the roles of MCH1 receptor signalling in ovariectomy (OVX)-induced obesity in female C57BL/6J mice, an animal model of postmenopausal obesity.
  
  
  METHODS
  The effects of blocking signalling via the MCH1 receptor on OVX-induced obesity was investigated by using Mch1r deficient (KO) mice and chronic treatment with a selective MCH1 receptor antagonist.
  
  
  RESULTS
  OVX induced body weight gain and increases in the weight of visceral fat and of liver; these effects were attenuated following OVX in Mch1r KO mice. OVX-induced triglyceride (TG) accumulation and elevated expression of lipogenic genes were significantly ameliorated in the liver of Mch1r KO mice. In agreement with these results, chronic i.c.v. infusion of a selective MCH1 receptor antagonist significantly reduced body weight gain, visceral fat and liver weights in OVX mice, and hepatic TG contents and lipogenic gene expression levels were normalized.
  
  
  CONCLUSIONS
  Our results indicate that MCH1 receptor signalling is involved in the development of fatty liver, as well as obesity, in OVX mice, and suggest a therapeutic potential for MCH1 receptor antagonists in the treatment of obesity and fatty liver.
authors.affiliation: Department of Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical Co. Ltd, Tsukuba, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Gomori
authors.forename: A
authors.initials: A
authors.lastname: Ishihara
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: H
authors.initials: H
authors.lastname: Matsushita
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: S
authors.initials: S
authors.lastname: Mashiko
authors.forename: H
authors.initials: H
authors.lastname: Iwaasa
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.forename: M A
authors.initials: MA
authors.lastname: Bednarek
authors.forename: S
authors.initials: S
authors.lastname: Qian
authors.forename: D J
authors.initials: DJ
authors.lastname: Macneil
authors.forename: A
authors.initials: A
authors.lastname: Kanatani
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015195:Drug Design; D005234:Fatty Liver / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D050155:Lipogenesis / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D010052:Ovariectomy; D017698:Postmenopause; D011897:Random Allocation; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors / Q000235:genetics*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D014280:Triglycerides / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
chemical_list: C491209:Mchr1 protein, mouse; D017481:Receptors, Somatostatin; D014280:Triglycerides